Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Olaparib in Metastatic Castration-Resistant Prostate Cancer
NCT02893917Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Radiographic Progression Free Survival up to 5 years. Started Aug 2017; status: active, not recruiting.
02
Drugs
cediranib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02893917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893917.